Arvinas to Present at Bank of America Securities Precision Oncology Conference

Rhea-AI Summary

Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, announced participation in a fireside chat at the Bank of America Securities Precision Oncology Conference on October 3, 2022, at 10:40 a.m. ET. The event will be accessible via a live audio webcast on Arvinas' website. The company is known for its innovative PROTAC® platform, which develops therapies aimed at degrading disease-causing proteins. Arvinas has several clinical-stage programs targeting prostate and breast cancers, reinforcing its commitment to advancing treatment options for severe diseases.

NEW HAVEN, Conn., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Bank of America Securities Precision Oncology Conference taking place virtually on Monday, October 3 at 10:40 a.m. ET.

A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.

About Arvinas
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC^® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC^® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC^® protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs: bavdegalutamide and ARV-766 for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.

Contacts

Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com

Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com

FAQ

When is Arvinas participating in the Bank of America Securities Precision Oncology Conference?

Arvinas will participate in the conference on October 3, 2022, at 10:40 a.m. ET.

How can I listen to Arvinas' presentation at the oncology conference?

You can listen to the live audio webcast of Arvinas' presentation on the company's website.

What is the focus of Arvinas' drug development?

Arvinas focuses on targeted protein degradation using its PROTAC® Discovery Engine platform to create therapies that degrade disease-causing proteins.

What clinical-stage programs does Arvinas currently have?

Arvinas has investigational programs for bavdegalutamide, ARV-766 targeting prostate cancer, and ARV-471 for ER+/HER2- breast cancer.

What disease areas is Arvinas targeting with its therapies?

Arvinas is targeting debilitating and life-threatening diseases, including prostate and breast cancers.